Market News (Page 86) - TendieTensor

Market News Page 86 of 159 • 3,975 articles

Legrand Acquires Avtron Power Solutions, a Global Provider of Load Banks & Power Quality Solutions

GlobeNewswire Inc. • Brian Dibella

Legrand Acquires Avtron Power Solutions, a Global Provider of Load Banks & Power Quality Solutions

11/07/2025 09:00 AM • Legrand has acquired Avtron Power Solutions, a global provider of load banks and power quality solutions with 600 employees and nearly $350 million in expected 2025 revenue. The acquisition supports Legrand's Ambition 2030 growth strategy targeting energy transition and datacenter solutions.

LGRDY - Expanding product portfolio, pursuing strategic growth, acquiring a complementary business in high-growth markets

#acquisition #power solutions #infrastructure #datacenters #energy transition

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

GlobeNewswire Inc. • Neonc Technologies

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

11/07/2025 09:00 AM • NeOnc Technologies will host an investor conference call to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial, focusing on intranasal delivery of NEO100 for treating recurrent high-grade malignant glioma.

NTHI - Company is presenting promising clinical trial data, hosting an investor conference, and demonstrating progress in brain cancer treatment research

#clinical trial #brain tumor #glioma #intranasal delivery #cancer research

$MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025$

GlobeNewswire Inc. • Mink Therapeutics

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

11/07/2025 09:00 AM • MiNK Therapeutics presented clinical results showing promising immune cell therapy agenT-797 demonstrated durable responses and immune reactivation in patients with checkpoint-resistant solid tumors, with some patients experiencing complete remission lasting over two years.

TMO - Offers wide-ranging CDMO services including API development, biologics, and gene therapy manufacturing
INKT - Reported breakthrough clinical results with agenT-797, showing durable responses across multiple cancer types, potential to overcome treatment resistance, and favorable safety profile

#immunotherapy #cell therapy #cancer treatment #iNKT #checkpoint inhibitors

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

GlobeNewswire Inc. • Bioage Labs, Inc.

BioAge Labs to Present at Jefferies Global Healthcare Conference in London

11/07/2025 09:00 AM • BioAge Labs will present at the Jefferies Global Healthcare Conference in London, with CEO Kristen Fortney and CFO Dov Goldstein participating in a fireside chat and one-on-one meetings, discussing their clinical-stage biotechnology work on metabolic disease therapies.

BIOA - Company is actively presenting at a major healthcare conference, advancing clinical trials for BGE-102, and developing innovative therapeutic candidates targeting metabolic aging pathways

#biotechnology #metabolic diseases #aging #clinical-stage #conference

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire Inc. • Io Biotech

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

11/07/2025 09:00 AM • IO Biotech presented pre-clinical data on two therapeutic cancer vaccine candidates, IO112 and IO170, at the Society for Immunotherapy of Cancer's Annual Meeting. The candidates target arginase 1 and TGF-β, demonstrating potential anti-tumor activities and immune microenvironment modulation.

IOBT - Company presented promising pre-clinical data for two new vaccine candidates, highlighting potential advancements in cancer immunotherapy and plans to file an Investigational New Drug Application in 2026

#cancer vaccine #immunotherapy #pre-clinical data #T-win platform #tumor microenvironment

Today's Marketplace discusses state of M&A with Creighton University's Tirimba Obonyo and Moelis's Mark Henkels

Benzinga • Globe Newswire

Today's Marketplace discusses state of M&A with Creighton University's Tirimba Obonyo and Moelis's Mark Henkels

11/07/2025 08:42 AM • Experts from Creighton University and Moelis & Company discussed the current mergers and acquisitions landscape, highlighting challenges like tariffs, interest rates, and valuation complexities that have led to a 9% drop in M&A activity in the first half of the year.

MC - Mark Henkels noted challenges in deal-making due to higher interest rates, but also highlighted ongoing strategic transactions and creative deal structuring

#M&A #mergers #acquisitions #interest rates #tariffs #valuation

Constellation Energy Narrows 2025 Guidance, Signaling Confidence in Execution

Investing.com • Timothy Fries

Constellation Energy Narrows 2025 Guidance, Signaling Confidence in Execution

11/07/2025 08:40 AM • Constellation Energy reported Q3 2025 financial results with revenue of $6.57 billion, slightly below EPS expectations but showing year-over-year growth. The company narrowed its full-year guidance and is preparing for a merger with Calpine Corporation, focusing on clean and reliable power generation.

CEG - Company showed year-over-year earnings growth, narrowed guidance confidently, progressed on strategic initiatives like Calpine merger and Conowingo Dam settlement, and maintained focus on clean energy strategy

#clean energy #nuclear energy #financial guidance #merger #sustainable power

GES SECURITIES ALERT: Guess?, Inc. $16.75 Merger with Authentic Brands Triggers Investigation – Shareholders Notified to Contact BFA Law

Benzinga • Globe Newswire

GES SECURITIES ALERT: Guess?, Inc. $16.75 Merger with Authentic Brands Triggers Investigation – Shareholders Notified to Contact BFA Law

11/07/2025 08:36 AM • Securities law firm Bleichmar Fonti & Auld LLP is investigating Guess's board of directors and executive officers for potential breaches of fiduciary duties in their $16.75 per share sale to Authentic Brands Group.

CROX - Trading at a cheap valuation (enterprise value-to-EBIT of 6), strong international growth of 16.4%, and significant stock buybacks reducing shares outstanding
GES - The article suggests potential misconduct by board members and executives in the merger process, with allegations of possible breaches of fiduciary responsibilities to shareholders

#merger #securities investigation #fiduciary duty #shareholder litigation

The Motley Fool • Robert Izquierdo

Is ASML Stock a Buy Now?

11/07/2025 08:34 AM • ASML, a Dutch semiconductor equipment manufacturer, has seen significant stock growth in 2025 due to the AI boom, holding a technological monopoly on extreme ultraviolet lithography systems critical for advanced chip production.

ASML - Strong market position with technological monopoly, expected 15% revenue growth in fiscal 2025, benefiting from AI chip demand despite geopolitical challenges

#AI #semiconductor #lithography #chip manufacturing #technology

Stock Market Today: S&P 500, Nasdaq Futures Down As Tech Stocks Fall— Tesla, Expedia, IREN, Archer Aviation In Focus (UPDATED)

Benzinga • Rishabh Mishra

Stock Market Today: S&P 500, Nasdaq Futures Down As Tech Stocks Fall— Tesla, Expedia, IREN, Archer Aviation In Focus (UPDATED)

11/07/2025 08:31 AM • U.S. stock futures rose on Friday after Thursday's tech-led market decline, with key focus on companies like Tesla, Expedia, and Archer Aviation. Market sentiment was mixed, with concerns about AI investments and potential economic indicators.

CCL - Strong revenue recovery, 10 consecutive quarters of record quarterly revenue, trading at low earnings multiple, and increasing consumer demand for cruises
TSLA - Stock rose 2.08% after shareholders approved CEO Elon Musk's pay package

#stock market #futures #tech stocks #AI #earnings #Federal Reserve

Microsoft: Why Investors Shouldn’t Fear the Dip in Stock

Investing.com • Chris Markoch

Microsoft: Why Investors Shouldn’t Fear the Dip in Stock

11/07/2025 08:31 AM • Microsoft's stock has dipped 2% post-earnings due to significant AI and cloud infrastructure investments, but long-term investors are advised not to panic as the company's fundamentals remain strong and the current volatility may present a buying opportunity.

MSFT - Despite short-term stock price decline, the article suggests the company's long-term prospects remain solid, with consistent dividend growth, strong fundamentals, and strategic investments in AI and cloud technologies

#Microsoft #AI #cloud infrastructure #stock investment #long-term strategy

Bath & Body Works Declares Cash Dividend

Benzinga • Globe Newswire

Bath & Body Works Declares Cash Dividend

11/07/2025 08:30 AM • Bath & Body Works announced a quarterly cash dividend of $0.20 per share, payable on December 5, 2025, to shareholders of record as of November 21, 2025.

UBER - Mentioned as a recent partnership with Lucid, but no specific sentiment analysis provided
BBWI - Company is maintaining consistent dividend payments, indicating financial stability and commitment to shareholder value

#dividend #quarterly #cash dividend #shareholders

BlackSky CEO Brian O'Toole Named 'Executive of the Year' at the 2025 Greater Washington GovCon Awards

Benzinga • Business Wire

BlackSky CEO Brian O'Toole Named 'Executive of the Year' at the 2025 Greater Washington GovCon Awards

11/07/2025 08:30 AM • BlackSky Technology CEO Brian O'Toole was honored as 'Executive of the Year' in the $75 to $300 million annual revenue category, recognizing his leadership in space-based intelligence and contributions to the government contracting industry.

TSLA - Mentioned as a competitive benchmark in the EV market
BKSY - The article highlights the company's achievements, industry leadership, and CEO's recognition, indicating strong performance and positive organizational momentum

#Earth observation #geospatial intelligence #satellite #government contracts #space technology

Warren Buffett's Warning to Wall Street has Reached Deafening Levels: 3 Things You Should Do Before 2026.

The Motley Fool • James Brumley

Warren Buffett's Warning to Wall Street has Reached Deafening Levels: 3 Things You Should Do Before 2026.

11/07/2025 08:15 AM • Warren Buffett is cautious about current stock market valuations, holding $381.6 billion in cash and suggesting investors prepare for a potential market correction by maintaining liquidity, identifying high-quality long-term stocks, and monitoring market trends.

XRT - Trailing S&P 500 performance and experiencing economic uncertainties in the retail sector
BRK.A - Holding significant cash reserves indicates caution about current market conditions, but not completely abandoning stock investments

#Warren Buffett #market valuation #cash reserves #investment strategy #stock market correction

IES Holdings to Acquire Gulf Island Fabrication

Benzinga • Globe Newswire

IES Holdings to Acquire Gulf Island Fabrication

11/07/2025 08:15 AM • IES Holdings will acquire Gulf Island Fabrication for $12.00 per share, representing a 52% premium, in a strategic move to expand infrastructure and data center service capabilities.

IESC - Expanding service capabilities, strategic acquisition at a premium, complementary business with potential for growth in infrastructure and data center markets

#acquisition #steel fabrication #infrastructure #data centers #merger

Legacy Housing Announces Agreement to Purchase Assets of AmeriCasa Solutions, LLC and Addition of New Senior Management

Benzinga • Globe Newswire

Legacy Housing Announces Agreement to Purchase Assets of AmeriCasa Solutions, LLC and Addition of New Senior Management

11/07/2025 08:14 AM • Legacy Housing Corporation has agreed to purchase the assets of AmeriCasa Solutions, including its FutureHomeX® Platform, in an all-cash transaction. Norman Newton, AmeriCasa's CEO, will join Legacy Housing as Chief Revenue Officer to help accelerate sales growth and technology integration.

LEGH - Expanding business through strategic acquisition, adding new technology platform, and bringing experienced leadership to drive growth

#manufactured homes #acquisition #technology platform #sales growth #strategic partnership

S&P 500: Price Weakness Signals Potential Trend Change

Investing.com • Peter B. Levant

S&P 500: Price Weakness Signals Potential Trend Change

11/07/2025 08:13 AM • The S&P 500 is showing technical weakness, closing below multiple moving averages and potentially signaling a short-term trend reversal. The critical 50-day moving average is being tested, which could trigger systematic selling if breached.

BRKRP - Actively expanding capabilities through strategic investments and acquisitions, such as acquiring Bridge12's Electron Paramagnetic Resonance business and investing in RECIPE Chemicals + Instruments
AAPL - Mentioned in market movers list with minimal price movement (-0.14%)

#S&P 500 #market trend #technical analysis #moving averages #market correction

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

GlobeNewswire Inc. • Sanofi And Regeneron

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

11/07/2025 08:00 AM • Sanofi and Regeneron's Dupixent demonstrated significant improvements in treating allergic fungal rhinosinusitis (AFRS) in a phase 3 study, with the FDA accepting the supplemental biologics license application for priority review.

SNY - Positive clinical trial results, FDA priority review acceptance, potential new treatment indication expanding Dupixent's market

#Dupixent #AFRS #clinical trial #FDA #phase 3 study

Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea

GlobeNewswire Inc. • Alexis Leroy

Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea

11/07/2025 08:00 AM • Karbon-X is expanding its mangrove restoration efforts from Senegal to the Konkouré Delta in Guinea, focusing on coastal restoration, biodiversity protection, and community resilience through blue carbon projects.

KARX - Company is demonstrating proactive environmental leadership by scaling successful mangrove restoration projects, generating carbon reductions, and creating community benefits across West Africa

#mangrove #blue carbon #coastal restoration #climate investment #sustainability

Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

GlobeNewswire Inc. • Judy Matthews

Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

11/07/2025 08:00 AM • Iterum Therapeutics will release its third quarter 2025 financial results on November 14, 2025, with a conference call to discuss results and provide a business update. The company has received FDA approval for ORLYNVAH, an oral antibiotic for treating urinary tract infections.

DE - Mentioned as part of newly elected Board of Directors without specific context
ITRM - Company received FDA approval for ORLYNVAH, has Fast Track and QIDP designations, and is hosting a financial results conference call, indicating ongoing business development and progress

#antibiotics #financial results #FDA approval #multi-drug resistant pathogens

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

GlobeNewswire Inc. • Immunocore Holdings Plc

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

11/07/2025 08:00 AM • Immunocore announced Phase 1 trial results for IMC-I109V, a T cell receptor bispecific candidate targeting hepatitis B virus, showing promising dose-dependent HBsAg reduction and a generally manageable safety profile.

IMCR - Positive trial results demonstrating potential efficacy and safety of IMC-I109V, with dose-dependent HBsAg reduction and manageable adverse events

#hepatitis B #immunotherapy #clinical trial #T cell receptor #bispecific #antiviral

Dycom Industries, Inc. to Host Fiscal 2026 Third Quarter Results Conference Call

GlobeNewswire Inc. • Callie Tomasso

Dycom Industries, Inc. to Host Fiscal 2026 Third Quarter Results Conference Call

11/07/2025 08:00 AM • Dycom Industries will host a fiscal 2026 third quarter results conference call on November 19, 2025, at 9:00 a.m. ET, with options for live audio webcast and replay.

DY - Standard quarterly earnings conference call announcement with no explicit positive or negative financial indicators

#conference call #earnings #investor relations #telecommunications

Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...

GlobeNewswire Inc. • Sanofi And Regeneron

Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...

11/07/2025 08:00 AM • A phase 3 clinical study of Dupixent demonstrated significant improvements in treating allergic fungal rhinosinusitis (AFRS), reducing sinus opacification, nasal congestion, and nasal polyps. The FDA has accepted the supplemental Biologics License Application with priority review.

SNY - Positive clinical trial results with potential new FDA-approved indication for Dupixent, expanding the drug's market potential

#Dupixent #AFRS #clinical trial #FDA #rhinosinusitis

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

GlobeNewswire Inc. • Atea Pharmaceuticals

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

11/07/2025 08:00 AM • Atea Pharmaceuticals presented modeling data showing their combination drug regimen of bemnifosbuvir and ruzasvir could potentially provide a short-duration, highly effective treatment for hepatitis C virus, with near-complete viral inhibition and a modeled cure time of 7-8 weeks.

AVIR - Company presented promising research data demonstrating high efficacy of their drug combination, with potential to transform HCV treatment landscape, achieve high sustained virologic response rates, and address patient needs

#hepatitis C virus #antiviral therapeutics #bemnifosbuvir #ruzasvir #clinical trials

AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call

GlobeNewswire Inc. • Tom Divine

AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call

11/07/2025 08:00 AM • AirJoule Technologies will report its third quarter 2025 financial results on November 13, 2025, with a conference call and Q&A session scheduled for November 14, 2025 at 8:30 AM ET.

A - Engaged in collaborative efforts to enhance biomolecular analysis technologies by partnering with Isospec Analytics
AIRJ - Standard financial reporting announcement with no explicit positive or negative indicators

#financial results #conference call #quarterly earnings #investor relations